Skip to main content
Top
Published in: Clinical Rheumatology 1/2013

01-01-2013 | Brief Report

Clinical interest of bone marrow aspiration in rheumatology: a practice-based observational study of 257 bone marrow aspirations

Authors: Amélie Loctin, François Bailly, Davy Laroche, Christian Tavernier, Jean-Francis Maillefert, Paul Ornetti

Published in: Clinical Rheumatology | Issue 1/2013

Login to get access

Abstract

Bone marrow aspiration (BMA) can be performed by rheumatologists for diagnostic purposes in clinical practice. The aim of the study was to assess professional practices of hospital-based rheumatologists with regard to BMA in order to identify the relevant indications. A retrospective observational study in patients hospitalised in a French university hospital was conducted between 2005 and 2011. All of the patients who had a BMA in the rheumatology department during the study period were included. Clinical indication, number and results of BMA and of bone marrow biopsy (BMB) were collected. Stage and treatment of the haematological disease implemented following the BMA were described. Two hundred fifty-seven BMAs and 79 BMBs were performed during the study period. Of the BMAs, 14.1 % were pathological: myeloma (n = 12), malignant B cell non-Hodgkin’s lymphoma (n = 6), myelodysplastic syndrome (n = 6), chronic lymphoid leukaemia (n = 4), Waldenstrom’s disease (n = 3), chronic myelomonocytic leukaemia (n = 2), hairy cell leukaemia (n = 1) and acute lymphoblastic leukaemia (n = 1). Eight of the 14 pathological BMBs were associated with normal BMA. BMAs were performed equally for gammaglobulin abnormalities (monoclonal peak = 45 % of indications, hypogammaglobulinemia = 6 %) and for other reasons (haemogram abnormality = 24 %, skeletal osteolysis = 6 %, unexplained inflammatory syndrome = 5 %, lymph node disease = 4 % and others). In clinical rheumatology, BMA may reveal two major types of malignant haematological diseases: myeloma with poor prognostic factors justifying polychemotherapy and autologous grafts and, in contrast, slowly evolving B cell lymphoid haemopathies. Given the additional risk in some types of chronic inflammatory rheumatism, BMB should be performed more frequently in certain specific situations (skeletal or lymph node tumour and unexplained inflammatory syndrome).
Literature
1.
go back to reference Hodges A, Koury MJ (1996) Needle aspiration and biopsy in the diagnosis and monitoring of bone marrow diseases. Clin Lab Sci 9(6):349–353PubMed Hodges A, Koury MJ (1996) Needle aspiration and biopsy in the diagnosis and monitoring of bone marrow diseases. Clin Lab Sci 9(6):349–353PubMed
3.
go back to reference Bain BJ (2006) Morbidity associated with bone marrow aspiration and trephine biopsy—a review of UK data for 2004. Haematologica 91(9):1293–1294PubMed Bain BJ (2006) Morbidity associated with bone marrow aspiration and trephine biopsy—a review of UK data for 2004. Haematologica 91(9):1293–1294PubMed
4.
go back to reference Manganelli P, Fietta P, Quaini F (2006) Hematologic manifestations of primary Sjogren’s syndrome. Clin Exp Rheumatol 24(4):438–448PubMed Manganelli P, Fietta P, Quaini F (2006) Hematologic manifestations of primary Sjogren’s syndrome. Clin Exp Rheumatol 24(4):438–448PubMed
5.
go back to reference Bida JP, Kyle RA, Therneau TM, Melton LJ 3rd, Plevak MF, Larson DR et al (2009) Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc 84(8):685–693PubMedCrossRef Bida JP, Kyle RA, Therneau TM, Melton LJ 3rd, Plevak MF, Larson DR et al (2009) Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc 84(8):685–693PubMedCrossRef
6.
go back to reference Bird J, Behrens J, Westin J, Turesson I, Drayson M, Beetham R et al (2009) UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 147(1):22–42PubMedCrossRef Bird J, Behrens J, Westin J, Turesson I, Drayson M, Beetham R et al (2009) UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 147(1):22–42PubMedCrossRef
7.
go back to reference Lee SH, Erber WN, Porwit A, Tomonaga M, Peterson LC (2008) ICSH guidelines for the standardization of bone marrow specimens and reports. Int J Lab Hematol 30(5):349–364PubMedCrossRef Lee SH, Erber WN, Porwit A, Tomonaga M, Peterson LC (2008) ICSH guidelines for the standardization of bone marrow specimens and reports. Int J Lab Hematol 30(5):349–364PubMedCrossRef
8.
go back to reference Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA et al (2010) Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 150(1):28–38PubMed Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA et al (2010) Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 150(1):28–38PubMed
9.
go back to reference Pertuiset ELV (2011) Gammapathies de signification indéterminée : nouveautés diagnostiques, pronostiques, recommandations. Actualités Rhumatologiques Pertuiset ELV (2011) Gammapathies de signification indéterminée : nouveautés diagnostiques, pronostiques, recommandations. Actualités Rhumatologiques
11.
go back to reference Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR et al (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354(13):1362–1369PubMedCrossRef Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR et al (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354(13):1362–1369PubMedCrossRef
12.
go back to reference Beauvillain CJP, Chevaille A (2011) Immunoglobulines monoclonales: méthodes diagnostiques en. Revue francophone des laboratoires Beauvillain CJP, Chevaille A (2011) Immunoglobulines monoclonales: méthodes diagnostiques en. Revue francophone des laboratoires
13.
go back to reference IMWG (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121(5):749–757CrossRef IMWG (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121(5):749–757CrossRef
14.
go back to reference Kyle RA, Rajkumar SV (2007) Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol 139(5):730–743PubMedCrossRef Kyle RA, Rajkumar SV (2007) Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol 139(5):730–743PubMedCrossRef
15.
go back to reference Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346(8):564–569PubMedCrossRef Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346(8):564–569PubMedCrossRef
16.
go back to reference Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G et al (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24(6):1121–1127PubMedCrossRef Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G et al (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24(6):1121–1127PubMedCrossRef
17.
go back to reference Katzmann JA (2009) Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev 30(3):105–111PubMed Katzmann JA (2009) Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev 30(3):105–111PubMed
18.
go back to reference Garton MJ, Keir G, Dickie A, Steven M, Rennie JA (2006) Prevalence and long-term significance of paraproteinaemia in rheumatoid arthritis. Rheumatology 45(3):355–356PubMedCrossRef Garton MJ, Keir G, Dickie A, Steven M, Rennie JA (2006) Prevalence and long-term significance of paraproteinaemia in rheumatoid arthritis. Rheumatology 45(3):355–356PubMedCrossRef
19.
go back to reference Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR et al (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89(6):888–892PubMed Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR et al (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89(6):888–892PubMed
20.
go back to reference Zhang QY, Foucar K (2009) Bone marrow involvement by Hodgkin and non-Hodgkin lymphomas. Hematol Oncol Clin North Am 23(4):873–902PubMedCrossRef Zhang QY, Foucar K (2009) Bone marrow involvement by Hodgkin and non-Hodgkin lymphomas. Hematol Oncol Clin North Am 23(4):873–902PubMedCrossRef
21.
go back to reference Samson M, Audia S, Lakomy D, Bonnotte B, Tavernier C, Ornetti P (2011) Stratégie diagnostique devant la découverte d’une hypogammaglobulinemie en rhumatologie. Rev Rhum 78(2):122–127CrossRef Samson M, Audia S, Lakomy D, Bonnotte B, Tavernier C, Ornetti P (2011) Stratégie diagnostique devant la découverte d’une hypogammaglobulinemie en rhumatologie. Rev Rhum 78(2):122–127CrossRef
22.
go back to reference Atac B, Lawrence C, Goldberg SN (1991) Metastatic tumor: the complementary role of the marrow aspirate and biopsy. Am J Med Sci 302(4):211–213PubMedCrossRef Atac B, Lawrence C, Goldberg SN (1991) Metastatic tumor: the complementary role of the marrow aspirate and biopsy. Am J Med Sci 302(4):211–213PubMedCrossRef
23.
go back to reference Hot A, Coppéré B, Pérard L, French M, Rousset H, Durand DV et al (2006) Contribution de la biopsie ostéomédullaire au diagnostic des syndromes inflammatoires biologiques chroniques. La Rev Méd Interne 27(S3):412–413CrossRef Hot A, Coppéré B, Pérard L, French M, Rousset H, Durand DV et al (2006) Contribution de la biopsie ostéomédullaire au diagnostic des syndromes inflammatoires biologiques chroniques. La Rev Méd Interne 27(S3):412–413CrossRef
24.
go back to reference Manion EM, Rosenthal NS (2008) Bone marrow biopsies in patients 85 years or older. Am J Clin Pathol 130(5):832–835PubMedCrossRef Manion EM, Rosenthal NS (2008) Bone marrow biopsies in patients 85 years or older. Am J Clin Pathol 130(5):832–835PubMedCrossRef
Metadata
Title
Clinical interest of bone marrow aspiration in rheumatology: a practice-based observational study of 257 bone marrow aspirations
Authors
Amélie Loctin
François Bailly
Davy Laroche
Christian Tavernier
Jean-Francis Maillefert
Paul Ornetti
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 1/2013
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-012-2097-y

Other articles of this Issue 1/2013

Clinical Rheumatology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.